Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Ottestad L, Fronth L, Rajendiran S, Hege Aksnes L, Eikesdal HP, Støre Blix E, Ewertz M.

Acta Oncol. 2019 Mar;58(3):385-387. doi: 10.1080/0284186X.2019.1566771. Epub 2019 Feb 23. No abstract available.

PMID:
30798641
2.

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN.

Oncotarget. 2017 Jan 3;8(1):1074-1082. doi: 10.18632/oncotarget.13718.

3.

Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.

Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J, Friend SH, Stolovitzky G, Aparicio S, Caldas C, Børresen-Dale AL.

Sci Transl Med. 2013 Apr 17;5(181):181re1. doi: 10.1126/scitranslmed.3006112.

4.

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V.

ISRN Oncol. 2012;2012:176789. doi: 10.5402/2012/176789. Epub 2012 May 14.

5.

Radiation-induced effects on gene expression: an in vivo study on breast cancer.

Helland A, Johnsen H, Frøyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Børresen-Dale AL.

Radiother Oncol. 2006 Aug;80(2):230-5. Epub 2006 Aug 4.

PMID:
16890317
6.

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J.

Breast Cancer Res. 2006;8(2):R13. Epub 2006 Mar 15. Erratum in: Breast Cancer Res. 2006;8(3):406.

7.

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.

Helle SI, Mietlowski W, Guastalla JP, Szakolczai I, Bajetta E, Sommer H, Baltali E, Pinter T, Csepreghy M, Ottestad L, Boni C, Bryce C, Klijn JG, Lønning PE.

Eur J Cancer. 2005 Mar;41(5):694-701. Epub 2005 Jan 21.

PMID:
15763644
8.

[Breast cancer patients' assessment of waiting time before radiotherapy].

Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W.

Tidsskr Nor Laegeforen. 2003 Jun 12;123(12):1685-6. Norwegian.

PMID:
12821991
9.

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L.

J Clin Oncol. 2002 Aug 1;20(15):3219-24.

PMID:
12149294
10.

Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast.

Suo Z, Bjaamer A, Ottestad L, Nesland JM.

Ultrastruct Pathol. 2001 Sep-Oct;25(5):349-56.

PMID:
11758715
11.

Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.

Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Einstein Lønning P.

Clin Cancer Res. 2001 May;7(5):1230-6.

12.

Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM.

Laake K, Odegård A, Andersen TI, Bukholm IK, Kåresen R, Nesland JM, Ottestad L, Shiloh Y, Børresen-Dale AL.

Genes Chromosomes Cancer. 1997 Mar;18(3):175-80.

PMID:
9071570
13.
14.

[Chemotherapy-induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma].

Schjølseth SA, Hagen T, Ottestad L, Jakobsen E.

Tidsskr Nor Laegeforen. 1995 Nov 10;115(27):3371-3. Norwegian.

PMID:
7491579
15.

Prognostic significance of TP53 alterations in breast carcinoma.

Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL.

Br J Cancer. 1993 Sep;68(3):540-8.

16.

Flow cytometric DNA analysis as prognostic factor in human breast carcinoma.

Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fosså SD, Tveit KM.

Pathol Res Pract. 1993 May;189(4):405-10.

PMID:
8351241
17.

Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL.

Acta Oncol. 1993;32(3):289-94.

PMID:
8100712
18.

Screening for germ line TP53 mutations in breast cancer patients.

Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D, et al.

Cancer Res. 1992 Jun 1;52(11):3234-6.

19.

Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas.

Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, Børresen AL.

Genes Chromosomes Cancer. 1992 Mar;4(2):113-21.

PMID:
1373310
20.

Invasive lobular carcinoma of the breast. The importance of an alveolar growth pattern.

Nesland JM, Grude TH, Ottestad L, Johannessen JV.

Pathol Annu. 1992;27 Pt 1:233-47. Review. No abstract available.

PMID:
1736244
21.

The c-erbB-2 protein in primary and metastatic breast carcinomas.

Nesland JM, Ottestad L, Børresen AL, Tvedt KE, Holm R, Heikkilä R, Tveit K.

Ultrastruct Pathol. 1991 May-Jun;15(3):281-9.

PMID:
1678562
22.

C-erbB-2 protein and neuroendocrine expression in breast carcinomas.

Nesland JM, Ottestad L, Heikilla R, Holm R, Tveit K, Børresen AL.

Anticancer Res. 1991 Jan-Feb;11(1):161-7.

PMID:
1673329
23.
24.

The effect of pre-morbid height and weight on the survival of breast cancer patients.

Tretli S, Haldorsen T, Ottestad L.

Br J Cancer. 1990 Aug;62(2):299-303.

25.

Drug sensitivity testing of human breast cancer.

Tveit KM, Ottestad L.

Acta Oncol. 1990;29(3):335-8. Review.

PMID:
2194534
26.

Colony forming ability of human breast carcinomas: lack of prognostic significance.

Ottestad L, Tveit KM, Hannisdal E, Skrede M, Nesland JM, Gundersen S, Pihl A.

Br J Cancer. 1989 Aug;60(2):216-9.

27.

An ultrastructural study of benign and malignant breast epithelial cells. A search for tonofilaments.

Kotańska KM, Holm R, Ottestad L, Nesland JM.

J Submicrosc Cytol Pathol. 1989 Jul;21(3):469-74.

PMID:
2551480
28.

[Determination of estrogen receptors in fine-needle aspirates from breast carcinoma. A description of a method].

Lilleng R, Hagmar B, Myrtvedt M, Ottestad L.

Tidsskr Nor Laegeforen. 1989 May 30;109(15):1630-2. Norwegian. No abstract available.

PMID:
2741142
29.

Cultivation of human breast carcinoma in soft agar. Experience with 237 fresh tumour specimens.

Ottestad L, Tveit KM, Høifødt HK, Nesland JM, Vaage S, Høie J, Lund E, Pihl A.

Br J Cancer. 1988 Jul;58(1):8-12.

30.

An immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay.

Ottestad LO, Tveit KM, Nesland JM, Dybsjord I, Børmer O, Høie J, Pihl A.

Histol Histopathol. 1988 Jul;3(3):269-74.

PMID:
2980233
31.

Neuron specific enolase-positive breast carcinomas.

Erikstein B, Nesland JM, Ottestad L, Lund E, Johannessen JV.

Histol Histopathol. 1988 Jan;3(1):97-102.

PMID:
2980214
32.

Neuroendocrine activity in metastatic breast carcinomas.

Nesland JM, Holm R, Ottestad L, Karlsen KO, Johannessen JV.

APMIS Suppl. 1988;2:204-14.

PMID:
2846016
33.

[Implanted subcutaneous injection port. When is continuous venous access needed].

Saeter G, Ottestad L, Karlsen KO.

Tidsskr Nor Laegeforen. 1986 Mar 10;106(7):577-9. Norwegian. No abstract available.

PMID:
3961785

Supplemental Content

Loading ...
Support Center